Assessment of cardiotoxicity with cardiac biomarkers in cancer patients

Herz

Volumn 36, Issue 4, 2011, Pages 325-332

  Cardinale, D ^a   Cipolla, C M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Biomarkers; Cardiotoxins; Chemotherapy; Natriuretic peptides; Troponin I

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYTOSTATIC AGENT; DAUNORUBICIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; FATTY ACID BINDING PROTEIN; GLYCOGEN PHOSPHORYLASE B; IDARUBICIN; INTERLEUKIN 6; MITOXANTRONE; NATRIURETIC FACTOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TELMISARTAN; TRASTUZUMAB; TROPONIN I; TROPONIN T; VASCULOTROPIN INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MEGADOSE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEUKEMIA; LUNG EDEMA; METABOLIC SYNDROME X; METASTASIS; NEOPLASM; OBESITY; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959737449     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-011-3453-4     Document Type: Review

References (65)

1. Yeh ETH, Bickford C (2009) Cardiovascular complications of cancer therapy. J Am Coll Cardiol 53:2231-2247
2. Bonow RO, Bennett S, Casey DE Jr et al (2005) ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America. Circulation 112:1853-1887 (Pubitemid 41368160)
3. Carver JR, Shapiro CL, Ng A et al (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary effects. J Clin Oncol 25:3991-4008 (Pubitemid 47477279)
4. Silber JH, Cnaan A, Clark BJ et al (2004) Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22:820-828 (Pubitemid 41103593)
5. Verdecchia A, Francisci S, Brenner H et al (2007) Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-789
6. Yeh ET (2006) Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57:485-498
7. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960 (Pubitemid 350220427)
8. Mertens A, Liu Q, Neglia J et al (2008) Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 100:1368-1379
9. Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084 (Pubitemid 30207690)
10. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717 (Pubitemid 10218041)
11. Haq MM, Legha SS, Choksi J et al (1985) Doxorubicin-induced congestive heart failure in adults. Cancer 56:1361-1365 (Pubitemid 15230583)
12. Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213-220
13. Steinherz LJ, Graham T, Hurwitz R et al (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 89:942-949
14. Meinardi MT, Graaf WT van der, Veldhuisen DJ van et al (1999) Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25:237-247 (Pubitemid 29417681)
15. Healey Bird BRJ, Swain SM (2008) Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 14:14-24 (Pubitemid 351377973)
16. Nielsen D, Jensen JB, Dombernowsky P et al (1990) Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810 (Pubitemid 20382342)
17. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13:699-709 (Pubitemid 34567375)
18. Panteghini M (2006) The new definition of myocardial infarction and the impact of troponin determination on clinical practice. Int J Cardiol 106:298-306
19. O'Brien PJ (2008) Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245:206-218
20. Giannitsis E, Katus HA (2009) Troponins and high-sensitivity troponins as markers of necrosis in CAD and heart failure. Herz 34:600-606
21. Jensen JK, Atar D, Mickley H (2007) Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol 15:867-870 (Pubitemid 46365612)
22. Adamcova M, Sterba M, Simunek T et al (2005) Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 4:457-472 (Pubitemid 40723720)
23. Sparano JA, Brown DL, Wolff AC (2002) Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 25:301-311
24. Expert Working Group on Biomarkers of Drug-Induced Cardiac Toxicity report to the Non-clinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science (2002) http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3891B101Troponin. Outline.pdf NICE website press release
25. Adamcova M, Simunek T, Kaiserova H et al (2007) In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 237:218-228
26. Urbanova D, Urban L, Carter A et al (2006) Cardiac troponins - biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 53:183-190 (Pubitemid 43844375)
27. Lipshultz SE, Rifai N, Sallan SE et al (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641-2648 (Pubitemid 27451357)
28. Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950-961
29. Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517-522
30. Cardinale D, Sandri MT, Martinoni A et al (2002) Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715 (Pubitemid 34567376)
31. Sandri MT, Cardinale D, Zorzino L et al (2003) Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 49:248-252 (Pubitemid 36143446)
32. Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754 (Pubitemid 38737923)
33. Auner HW, Tinchon C, Linkesch W et al (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82:218-222 (Pubitemid 36701012)
34. Specchia G, Buquicchio C, Pansini N et al (2005) Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 145:212-220 (Pubitemid 40692404)
35. Kilickap S, Barista I, Akgul E et al (2005) cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16:798-804 (Pubitemid 40767103)
36. Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916
37. Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481 (Pubitemid 44901520)
38. Dolci A, Dominici R, Cardinale D et al (2008) Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 130:688-695
39. Germanakis I, Anagnostatou N, Kalmanti M (2008) Troponins an natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 51:327-333
40. Goetze JP (2004) Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50:1503-1510
41. Berliner D, Angermann CE, Ertl G, Stork S (2009) Biomarkers in heart failure - better than history or echocardiography. Herz 24:581-588
42. Lüers C, Schmidt A, Wachter R et al (2010) Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure. Herz 35(7):488-495
43. Suzuki T, Hayashi D, Yamazaki T et al (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362-363 (Pubitemid 28368863)
44. Nousiainen T, Jantunen E, Vanninen E et al (1998) Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol 61:347-353 (Pubitemid 28551685)
45. Nousiainen T, Jantunen E, Vanninen E et al (1999) Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 62:135-141 (Pubitemid 29071274)
46. Hayakawa H, Komada Y, Hirayama M et al (2001) Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 37:4-9 (Pubitemid 32613628)
47. Okumura H, Iuchi K, Yoshida T et al (2000) Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104:158-163 (Pubitemid 32250128)
48. Sandri MT, Salvatici M, Cardinale D et al (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51:1405-1410
49. Zver S, Zadnik V, Bunc M et al (2008) Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 88:227-236
50. Erkus B, Demirtas S, Yarpuzlu AA et al (2007) Early prediction of anthracycline induced cardiotoxicity. Acta Pedriatr 96:506-509 (Pubitemid 46466109)
51. Vogelsang TW, Jensen RJ, Hesse B, Kjaer A (2008) BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline- induced cardiotoxicity. Int J Cardiol 29:193-197 (Pubitemid 351173366)
52. Tikanoja T, Riikonen P, Perkkiö M, Helenius T (1998) Serum N terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 31:73-78 (Pubitemid 28341019)
53. Nuver J, Smit AJ, Sleijfer DT et al (2004) Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40:701-706 (Pubitemid 38326620)
54. Nuver J, De Haas EC, Van Zweeden M et al (2010) Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 23:247-253
55. Vaughn DJ, Palmer SC, Carver JR et al (2008) Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112:1949-1953
56. Lemos JA de, O'Donoghue M (2007) The skinny on fatty acid-binding protein. J Am Coll Cardiol 50:2068-2070
57. Kilcullen N, Viswanathan K, Das R et al (2007) Heart-type fatty acid-binding protein predicts long term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 50:2061-2067 (Pubitemid 350087577)
58. O'Donoghue M, Lemos JA de, Morrow DA et al (2006) Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 114:550-557 (Pubitemid 44199644)
59. ElGhandour AH, El Sorady M, Azab S, ElRahman M (2009) Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rev e1-e6
60. Horacek JM, Vasatova M, Tichy M et al (2010) Thes use of cardiac biomarkers in detection of cardioxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 32:97-99
61. Hogye M, Mandi Y, Csanady M et al (2004) Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 94:249-251 (Pubitemid 38902885)
62. Mercuro G, Cadeddu C, Piras A et al (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12:1124-1133 (Pubitemid 350007024)
63. Cadeddu C, Piras A, Mantovani G et al (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160:487. e1-487. e7
64. Wouters KA, Kremer LC, Miller TL et al (2005) Protecting against anthracyclines-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131:561-578 (Pubitemid 43899624)
65. Ederhy S, Massard C, Dufaitre G et al (2010) Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase 1 trials. Invest New Drugs DOI 10.1007/s10637-010-9546-8